Evidence-based medicine: new in the search for evidence

The review is focused on discussing new trends in DM, rethinking the evidence base medicine with an emphasis on demonstrating the efficacy and safety of new therapeutic agents and medical technologies, from gene editing to AI algorithms. At the same time, clinical trials of drugs are also not standing still, there is active development, new approaches, methods and designs are being developed. The process of drug development, registration and market launch of any drug takes a significant period of time, requires high financial costs and human resources. The gold standard of evidence-based medicine was initially considered to be RCTs, but at the same time, they have objective disadvantages: limited sample, inability to control all factors; insufficient follow-up time,negative impact on participants, inability to determine cause-and-effect relationships; limited measurement methods, limited budget and others. This review discusses the trends in the methodology of clinical research. The active implementation of new designs such as Adaptive Clinical Trials, "Master" protocols including Umbrella Study, Basket Study, Platform Studies, Master Observational Trials and the increased use of Single Patient Trials (N-of-1 trials) are allowing studies to become more efficient, relevant and applicable to real-life health care practice settings and patient-centered. In the review, we also look at both the pros and cons of the expanded use of biomarkers and Digital Endpoints in clinical trials and virtual clinical trials, which use mathematical models to study patient heterogeneity and its impact on various therapeutic questions. The process of expertise and regulatory approval continues to slow down the entry of drugs into the pharmaceutical market. The review considers changes in the approaches of regulators (FDA, EMEA and Russian Ministry of Health) to the drug registration procedure. The COVID-19 pandemic and sanctions have led to the need to expand the list of drugs with authorized accelerated registration. However, accelerated registration raises many questions regarding the sufficiency of the level of evidence and safety. As we can see a deep synthesis and integration of all available data is needed to achieve the next generation of evidence-based medicine. The major challenge in the next two decades will be to exploit the potential of multidimensional evidence generation by extracting, collating and generating large data sets of natural course of disease, genomics and all other omics analyses, all published clinical trials, RWD to provide next generation evidence.

1. Вербицкая Е.В. Доказательная медицина: основные понятия, принципы поиска и оценки информации: методическое пособие / Е. В. Вербицкая; под ред. А. С. Колбина. — СПб.: РИЦ ПСПбГМУ, 2017. — 36 с. [Verbitskaya EV. Dokazatel'naya medicina: osnovnye ponyatiya, principy poiska i ocenki informacii: metodicheskoe posobie / EV Verbitskaya; ed by. AS Kolbin. SPb.: PPC PSPBGMU, 2017. (In Russ.)].

2. Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA. 1992 Nov 4;268(17):2420-5. doi: 10.1001/jama.1992.03490170092032.

3. Управление клиническими исследованиями / под общ. ред. Белоусова Д. Ю., Зырянова С. К., Колбина А. С. — 1-е изд. — М.: Буки Веди: Издательство ОКИ, 2017. — 676 с.: ил. — ISBN 978-5-4465-1602-5. [Upravlenie klinicheskimi issledovaniyami / Ed by Belousov DYU, Zyryanova SK, Kolbina AS. 1-e izd. Moscow: Buki Vedi: Publishing House OKI, 2017. (In Russ).].

4. Rethinking evidence in medicine. Nat Med. 2023 Jan;29(1):1. doi: 10.1038/s41591-022-02186-3.

5. Subbiah V. The next generation of evidence-based medicine. Nat Med. 2023 Jan;29(1):49-58. doi: 10.1038/s41591-022-02160-z.

6. Martin L, Hutchens M, Hawkins C, Radnov A. How much do clinical trials cost? Nat Rev Drug Discov. 2017 Jun;16(6):381-382. doi: 10.1038/nrd.2017.70.

7. Food and Drug Administration. Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry. 2019. [Online]. Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry.

8. Бондарева И. Б. Адаптивный дизайн в клинических исследованиях: преимущества и риски. Качественная клиническая практика. 2017;(3):23–34. [Bondareva IB. Adaptive design in clinical trials: benefits and risks. Kachestvennaya klinicheskaya praktika. 2017;(3):23–34. (In Russ.)]. Accessed: Jun. 19, 2023. [Online]. Available: https://www.clinvest.ru/jour/article/view/91/91.

9. Park JJH, Siden E, Zoratti MJ, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials. 2019 Sep 18;20(1):572. doi: 10.1186/s13063-019-3664-1.

10. Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med. 2017 Jul 6;377(1):62-70. doi: 10.1056/NEJMra1510062.

11. Dickson D, Johnson J, Bergan R, et al. The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. Cell. 2020 Jan 9;180(1):9-14. doi: 10.1016/j.cell.2019.12.009.

12. Das S, Lo AW. Re-inventing drug development: A case study of the I-SPY 2 breast cancer clinical trials program. Contemp Clin Trials. 2017 Nov;62:168-174. doi: 10.1016/j.cct.2017.09.002.

13. Redman MW, Papadimitrakopoulou VA, Minichiello K, et al. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol. 2020 Dec;21(12):1589-1601. doi: 10.1016/S1470-2045(20)30475-7.

14. Subbiah V, Puzanov I, Blay JY, et al. Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. Cancer Discov. 2020 May;10(5):657-663. doi: 10.1158/2159-8290.CD-19-1265.

15. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2018 Jan 1;36(1):7-13. doi: 10.1200/JCO.2017.73.6785.

16. Subbiah V, Cassier PA, Siena S, Garralda E, Paz-Ares L, Garrido P, Nadal E, Vuky J, Lopes G, Kalemkerian GP, Bowles DW, Seetharam M, Chang J, Zhang H, Green J, Zalutskaya A, Schuler M, Fan Y, Curigliano G. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat Med. 2022 Aug;28(8):1640-1645. doi: 10.1038/s41591-022-01931-y.

17. Normand ST. The RECOVERY Platform. N Engl J Med. 2021 Feb 25; 384(8):757-758. doi: 10.1056/NEJMe2025674.

18. Turner NC, Kingston B, Kilburn LS, et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020 Oct;21(10):1296-1308. doi: 10.1016/S1470-2045(20)30444-7.

19. Gold S, Roig M, Miranda J, et al. Platform trials and the future of evaluating therapeutic behavioural interventions. Nat Rev Psychol. 2022;1(1):7–8. doi: 10.1038/s44159-021-00012-0.

20. Dickson D, Johnson J, Bergan R, Owens R, Subbiah V, Kurzrock R. Snapshot: Trial Types in Precision Medicine. Cell. 2020 Apr 2;181(1):208-208.e1. doi: 10.1016/j.cell.2020.02.032.

21. Guyatt G, Sackett D, Adachi J, et al. A clinician's guide for conducting randomized trials in individual patients. CMAJ. 1988 Sep 15;139(6):497-503.

22. Kim J, Hu C, Moufawad El Achkar C, et al. Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. N Engl J Med. 2019 Oct 24;381(17):1644-1652. doi: 10.1056/NEJMoa1813279.

23. Ochoa D, Karim M, Ghoussaini M, et al. Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. Nat Rev Drug Discov. 2022 Aug;21(8):551. doi: 10.1038/d41573-022-00120-3.

24. Robb MA, McInnes PM, Califf RM. Biomarkers and Surrogate Endpoints: Developing Common Terminology and Definitions. JAMA. 2016 Mar 15;315(11):1107-8. doi: 10.1001/jama.2016.2240.

25. Landers M, Dorsey R, Saria S. Digital Endpoints: Definition, Benefits, and Current Barriers in Accelerating Development and Adoption. Digit Biomark. 2021 Sep 13;5(3):216-223. doi: 10.1159/000517885.

26. Desai A, Subbiah V. COVID-19 Pandemic and Cancer Clinical Trial Pandemonium: Finding the Silver Lining. J Immunother Precis Oncol. 2020 Nov 16;4(2):64-66. doi: 10.36401/JIPO-20-X7.

27. Soenksen LR, Ma Y, Zeng C, et al. Integrated multimodal artificial intelligence framework for healthcare applications. NPJ Digit Med. 2022 Sep 20;5(1):149. doi: 10.1038/s41746-022-00689-4.

28. Holford N, Ma SC, Ploeger BA. Clinical trial simulation: a review. Clin Pharmacol Ther. 2010 Aug;88(2):166-82. doi: 10.1038/clpt.2010.114.

29. Periodontal Market Size & Share Analysis — Industry Research Report — Growth Trends. https://www.mordorintelligence.com/industry-reports/virtual-clinical-trials-market (accessed Jul. 21, 2023).

30. FDA-Guidance. Digital Health Technologies for Remote Data Acquisition in Clinical Investigations, Guid. Ind. Investig. Other Stakeholders. 2021. Accessed: Jul. 21, 2023. [Online]. Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/digital-health-technologies-remote-data-acquisition-clinical-investigations.

31. Thomas KA, Kidziński Ł. Artificial intelligence can improve patients' experience in decentralized clinical trials. Nat Med. 2022 Dec;28(12):2462-2463. doi: 10.1038/s41591-022-02034-4.

32. Wong DR, Bhattacharya S, Butte AJ. Prototype of running clinical trials in an untrustworthy environment using blockchain. Nat Commun. 2019 Feb 22;10(1):917. doi: 10.1038/s41467-019-08874-y.

33. Семенов-Тян-Шанский В.Л., Бальцерович А.С., Сазонова А.Н., и др. 10 лет успеха — школа мониторов клинических исследований «CRA University». Ремедиум. 2021:(1);4-8. [Semenov-Tyan-Shanskiy VL, Bal’tserovich AS, Sazonova AN. CRA University — School of Clinical Trial Monitors: 10 years of success. Remedium. 2021:(1);4-8. (In Russ.)]. doi: 10.21518/1561-5936-2021-1-4-8.

34. Романов A.Н., Кондакова О.Н., Григорьев Ф.В., и др. Вычислительные методы и компьютерные технологии в разработке лекарственных средств. Структура и динамика молекулярных систем. 2008;2(4А): 441-453. [Romanov AN, Kondakova ON, Grigoriev FV, et al. Vychislitel'nye metody i komp'yuternye tekhnologii v razrabotke lekarstvennyh sredstv. Struktura i dinamika molekulyarnyh sistem. 2008;2(4А):441-453. (In Russ.)]. [Online]. Available: https://www.researchgate.net/publication/230633896_Vycislitelnye_metody_i_komputernye_tehnologii_v_razrabotke_lekarstvennyh_sredstv.

35. Федеральный закон от 12.04.2010 N 61-ФЗ «Об обращении лекарственных средств» (с изменениями и дополнениями) [Federal Law No. 61-FZ of 12.04.2010 "Ob obrashchenii lekarstvennyh sredstv" (with amendments and additions) (In Russ.)]. https://base.garant.ru/12174909/ (accessed Aug. 24, 2022).

36. Постановление Правительства РФ от 05.04.2022 N 593 «Об особенностях обращения лекарственных средств для медицинского применения в случае дефектуры или риска возникновения дефектуры лекарственных препаратов в связи с введением в отношении Российской Федерации ограничительных мер экономического характера» (с изменениями и дополнениями). [Decree of the Government of the Russian Federation of 05.04.2022 N 593 "Ob osobennostyah obrashcheniya lekarstvennyh sredstv dlya medicinskogo primeneniya v sluchae defektury ili riska vozniknoveniya defektury lekarstvennyh preparatov v svyazi s vvedeniem v otnos henii Rossijskoj Federacii ogranichitel'nyh mer ekonomicheskogo haraktera" (with amendments and additions). (In Russ.)]. https://base.garant.ru/404458632/ (accessed Jul. 27, 2023).

37. Постановление Правительства Российской Федерации от 27.05.2023 № 824 «О внесении изменений в постановление Правительства Российской Федерации от 5 апреля 2022 г. № 593». [Resolution of the Government of the Russian Federation of 27.05.2023 No. 824 "O vnesenii izmenenij v postanovlenie Pravitel'stva Rossijskoj Federacii ot 5 aprelya 2022 g. № 593". (In Russ.)]. http://publication.pravo.gov.ru/document/0001202306050018?pageSize=100&index=1 (accessed Jul. 27, 2023).

38. FDA. Accelerated Approval Program FDA. 2022. https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program (accessed Jul. 27, 2023).

39. Langreth R, Rutherford F, Milton I, et al. Drug Companies Are Minting Billions on Unproven Treatments With FDA Shortcut. 2023. [Online]. Available: https://www.bloomberg.com/news/articles/2023-05-14/fda-fast-tracked-drugs-make-companies-billions-on-unproven-claims.

40. Ramagopalan SV, Popat S, Gupta A, et al. Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment. JAMA Netw Open. 2022 Nov 1;5(11):e2239874. doi: 10.1001/ jamanetworkopen.2022.39874..

41. https://docs.eaeunion.org/docs/ru-ru/0127060/itia_24122014_doc.pdf

42. Cochrane A. (1972). Effectiveness and Efficiency: Random Reflections on Health Services. London: Nuffield Provincial Hospitals Trust.

43. Nordon C, Karcher H, Groenwold RH, et al. The "Efficacy-Effectiveness Gap": Historical Background and Current Conceptualization. Value Health. 2016 Jan;19(1):75-81. doi: 10.1016/j.jval.2015.09.2938.

44. Исследования реальной клинической практики. Обновлённые рекомендации 2023 года. / под общей редакцией Колбина А.С. — М.: Издательство ОКИ, 2023. — 222 с. : ил. ISBN 978-5-907715-17-2. [Issledovaniya real'noj klinicheskoj praktiki. Obnovlyonnye rekomendacii 2023 goda. / Ed by Kolbin AS. Moscow: Publishing House OKI, 2023. (In Russ.)].

45. Решение Совета ЕЭК № 78 (ред. от 17.03.2022) «О внесении изменений в Правила регистрации и экспертизы лекарственных средств для медицинского применения». [Decision of the EEC Council No. 78 (ed. dated 03/17/2022) "O vnesenii izmenenij v Pravila registracii i ekspertizy lekarstvennyh sredstv dlya medicinskogo primeneniya". (In Russ.)]. Режим доступа: https://docs.eaeunion.org/docs/ru-ru/01431480/err_18032022_36.

46. ICH Reflection Paper. ICH Reflection paper on proposed international harmonisation of real-world evidence terminology and convergence of general principles regarding planning and reporting of studies using real-world data, with a focus on effectiveness of medicines. https://www.ich.org

47. Петров В.И., Толкачев Б.Е. Количественная клиническая фармакология и пациент-ориентированные технологии здравоохранения: перспективы 2030. Ведомости Научного центра экспертизы средств медицинского применения. Регуляторные исследования и экспертиза лекарственных средств. 2022;12(2):205-213. [Petrov VI, Tolkachev BE. Quantitative clinical pharmacology and patient-centered healthcare technologies: perspectives 2030. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya. Regulyatornye issledovaniya i ekspertiza lekarstvennykh sredstv = Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation. 2022;12(2):205-213. (In Russ.)]. doi: 10.30895/1991-2919-2022-12-2-205-213.

48. Сычёв Д.А. Переход к персонализированной медицине — приоритет научно-технологического развития России. Фармакогенетика и фармакогеномика. 2017;(1):3-4. [Sychev DA. Perekhod k personalizirovannoj medicine — prioritet nauchno-tekhnologicheskogo razvitiya Rossii. Farmakogenetika i farmakogenomika. 2017;(1):3-4. (In Russ.)].

49. Этическая экспертиза биомедицинских исследований: руководство для комитетов по этике. / под общей ред. А.Л. Хохлова. — 3-е изд., перераб. и доп. — М.: Изд-во ОКИ, 2021. — 792 с.: ил. ISBN 978-5-4465-3406-7. [Eticheskaya ekspertiza biomedicinskih issledovanij: rukovodstvo dlya komitetov po etike. / Ed by AL Khokhlov. — 3rd ed., reprint. and additional. — Moscow: Publishing House OKI, 2021. (In Russ.)].